nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—MPO—Cisplatin—peripheral nervous system neoplasm	0.324	0.507	CbGbCtD
Tolmetin—PTGS2—Cisplatin—peripheral nervous system neoplasm	0.112	0.175	CbGbCtD
Tolmetin—PTGS2—Etoposide—peripheral nervous system neoplasm	0.11	0.172	CbGbCtD
Tolmetin—PTGS1—Etoposide—peripheral nervous system neoplasm	0.0929	0.145	CbGbCtD
Tolmetin—TDO2—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00525	0.0658	CbGpPWpGaD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—NF1—peripheral nervous system neoplasm	0.00281	0.0352	CbGpPWpGaD
Tolmetin—CXCL8—EBV LMP1 signaling—IFNB1—peripheral nervous system neoplasm	0.00268	0.0336	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—NTS—peripheral nervous system neoplasm	0.00227	0.0285	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00219	0.0274	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—CD34—peripheral nervous system neoplasm	0.00192	0.0241	CbGpPWpGaD
Tolmetin—CXCL8—ATF-2 transcription factor network—NF1—peripheral nervous system neoplasm	0.00189	0.0237	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—COX2—peripheral nervous system neoplasm	0.00189	0.0236	CbGpPWpGaD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—KNG1—peripheral nervous system neoplasm	0.00174	0.0218	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—EED—peripheral nervous system neoplasm	0.00144	0.018	CbGpPWpGaD
Tolmetin—Visual impairment—Tretinoin—peripheral nervous system neoplasm	0.00129	0.00461	CcSEcCtD
Tolmetin—Visual impairment—Isotretinoin—peripheral nervous system neoplasm	0.00129	0.00461	CcSEcCtD
Tolmetin—TDO2—Amino acid and derivative metabolism—TH—peripheral nervous system neoplasm	0.00127	0.016	CbGpPWpGaD
Tolmetin—Erythema multiforme—Tretinoin—peripheral nervous system neoplasm	0.00127	0.00452	CcSEcCtD
Tolmetin—Erythema multiforme—Isotretinoin—peripheral nervous system neoplasm	0.00127	0.00452	CcSEcCtD
Tolmetin—Cardiac failure congestive—Etoposide—peripheral nervous system neoplasm	0.00127	0.00451	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—TH—peripheral nervous system neoplasm	0.00125	0.0157	CbGpPWpGaD
Tolmetin—Gastrointestinal haemorrhage—Cisplatin—peripheral nervous system neoplasm	0.00125	0.00446	CcSEcCtD
Tolmetin—Tinnitus—Isotretinoin—peripheral nervous system neoplasm	0.00125	0.00446	CcSEcCtD
Tolmetin—Tinnitus—Tretinoin—peripheral nervous system neoplasm	0.00125	0.00446	CcSEcCtD
Tolmetin—Abdominal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00122	0.00434	CcSEcCtD
Tolmetin—Stomatitis—Dactinomycin—peripheral nervous system neoplasm	0.00119	0.00424	CcSEcCtD
Tolmetin—Dysuria—Alitretinoin—peripheral nervous system neoplasm	0.00119	0.00423	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Etoposide—peripheral nervous system neoplasm	0.00119	0.00422	CcSEcCtD
Tolmetin—Weight increased—Alitretinoin—peripheral nervous system neoplasm	0.00116	0.00412	CcSEcCtD
Tolmetin—Flatulence—Tretinoin—peripheral nervous system neoplasm	0.00115	0.0041	CcSEcCtD
Tolmetin—Flatulence—Isotretinoin—peripheral nervous system neoplasm	0.00115	0.0041	CcSEcCtD
Tolmetin—Weight decreased—Alitretinoin—peripheral nervous system neoplasm	0.00115	0.00409	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—SUZ12—peripheral nervous system neoplasm	0.00115	0.0144	CbGpPWpGaD
Tolmetin—Dysuria—Vincristine—peripheral nervous system neoplasm	0.00115	0.00408	CcSEcCtD
Tolmetin—Agranulocytosis—Dactinomycin—peripheral nervous system neoplasm	0.00114	0.00406	CcSEcCtD
Tolmetin—Drowsiness—Alitretinoin—peripheral nervous system neoplasm	0.00113	0.00403	CcSEcCtD
Tolmetin—Renal failure—Alitretinoin—peripheral nervous system neoplasm	0.00111	0.00397	CcSEcCtD
Tolmetin—Weight decreased—Vincristine—peripheral nervous system neoplasm	0.00111	0.00395	CcSEcCtD
Tolmetin—Stomatitis—Alitretinoin—peripheral nervous system neoplasm	0.00111	0.00393	CcSEcCtD
Tolmetin—Urinary tract infection—Alitretinoin—peripheral nervous system neoplasm	0.0011	0.00392	CcSEcCtD
Tolmetin—Hepatitis—Dactinomycin—peripheral nervous system neoplasm	0.0011	0.00391	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—TH—peripheral nervous system neoplasm	0.00109	0.0137	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—EED—peripheral nervous system neoplasm	0.00109	0.0136	CbGpPWpGaD
Tolmetin—Haematuria—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00385	CcSEcCtD
Tolmetin—Epistaxis—Alitretinoin—peripheral nervous system neoplasm	0.00107	0.00381	CcSEcCtD
Tolmetin—Stomatitis—Vincristine—peripheral nervous system neoplasm	0.00106	0.00379	CcSEcCtD
Tolmetin—Agranulocytosis—Alitretinoin—peripheral nervous system neoplasm	0.00106	0.00377	CcSEcCtD
Tolmetin—Abdominal discomfort—Cisplatin—peripheral nervous system neoplasm	0.00104	0.0037	CcSEcCtD
Tolmetin—Erythema multiforme—Dactinomycin—peripheral nervous system neoplasm	0.00104	0.00369	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Etoposide—peripheral nervous system neoplasm	0.00103	0.00368	CcSEcCtD
Tolmetin—CXCL8—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00102	0.0128	CbGpPWpGaD
Tolmetin—Hepatitis—Alitretinoin—peripheral nervous system neoplasm	0.00102	0.00362	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.00101	0.0127	CbGpPWpGaD
Tolmetin—Chest pain—Topotecan—peripheral nervous system neoplasm	0.001	0.00357	CcSEcCtD
Tolmetin—TDO2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000995	0.0125	CbGpPWpGaD
Tolmetin—Chest pain—Tretinoin—peripheral nervous system neoplasm	0.000995	0.00354	CcSEcCtD
Tolmetin—Chest pain—Isotretinoin—peripheral nervous system neoplasm	0.000995	0.00354	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—CDKN2A—peripheral nervous system neoplasm	0.000984	0.0123	CbGpPWpGaD
Tolmetin—Chest pain—Melphalan—peripheral nervous system neoplasm	0.000982	0.0035	CcSEcCtD
Tolmetin—Visual impairment—Alitretinoin—peripheral nervous system neoplasm	0.000981	0.00349	CcSEcCtD
Tolmetin—Erythema multiforme—Alitretinoin—peripheral nervous system neoplasm	0.000962	0.00342	CcSEcCtD
Tolmetin—Glossitis—Epirubicin—peripheral nervous system neoplasm	0.000962	0.00342	CcSEcCtD
Tolmetin—Anaphylactic shock—Topotecan—peripheral nervous system neoplasm	0.000962	0.00342	CcSEcCtD
Tolmetin—Oedema—Isotretinoin—peripheral nervous system neoplasm	0.000954	0.0034	CcSEcCtD
Tolmetin—Oedema—Tretinoin—peripheral nervous system neoplasm	0.000954	0.0034	CcSEcCtD
Tolmetin—Anaphylactic shock—Isotretinoin—peripheral nervous system neoplasm	0.000954	0.0034	CcSEcCtD
Tolmetin—Anaphylactic shock—Tretinoin—peripheral nervous system neoplasm	0.000954	0.0034	CcSEcCtD
Tolmetin—Renal failure—Cisplatin—peripheral nervous system neoplasm	0.00095	0.00338	CcSEcCtD
Tolmetin—Tinnitus—Alitretinoin—peripheral nervous system neoplasm	0.000949	0.00338	CcSEcCtD
Tolmetin—Oedema—Melphalan—peripheral nervous system neoplasm	0.000942	0.00335	CcSEcCtD
Tolmetin—Anaphylactic shock—Melphalan—peripheral nervous system neoplasm	0.000942	0.00335	CcSEcCtD
Tolmetin—Thrombocytopenia—Topotecan—peripheral nervous system neoplasm	0.000942	0.00335	CcSEcCtD
Tolmetin—Stomatitis—Cisplatin—peripheral nervous system neoplasm	0.000942	0.00335	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—ERBB2—peripheral nervous system neoplasm	0.000941	0.0118	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Tretinoin—peripheral nervous system neoplasm	0.000934	0.00332	CcSEcCtD
Tolmetin—Thrombocytopenia—Isotretinoin—peripheral nervous system neoplasm	0.000934	0.00332	CcSEcCtD
Tolmetin—Thrombocytopenia—Melphalan—peripheral nervous system neoplasm	0.000922	0.00328	CcSEcCtD
Tolmetin—Glossitis—Doxorubicin—peripheral nervous system neoplasm	0.00089	0.00317	CcSEcCtD
Tolmetin—Flatulence—Alitretinoin—peripheral nervous system neoplasm	0.000873	0.00311	CcSEcCtD
Tolmetin—Renal failure—Etoposide—peripheral nervous system neoplasm	0.00087	0.0031	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—SUZ12—peripheral nervous system neoplasm	0.000869	0.0109	CbGpPWpGaD
Tolmetin—Stomatitis—Etoposide—peripheral nervous system neoplasm	0.000863	0.00307	CcSEcCtD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—peripheral nervous system neoplasm	0.000854	0.0107	CbGpPWpGaD
Tolmetin—CXCL8—TSLP Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000854	0.0107	CbGpPWpGaD
Tolmetin—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.000848	0.00302	CcSEcCtD
Tolmetin—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.000848	0.00302	CcSEcCtD
Tolmetin—Dyspepsia—Topotecan—peripheral nervous system neoplasm	0.000847	0.00301	CcSEcCtD
Tolmetin—Dyspepsia—Tretinoin—peripheral nervous system neoplasm	0.00084	0.00299	CcSEcCtD
Tolmetin—Dyspepsia—Isotretinoin—peripheral nervous system neoplasm	0.00084	0.00299	CcSEcCtD
Tolmetin—Blood urea increased—Epirubicin—peripheral nervous system neoplasm	0.000837	0.00298	CcSEcCtD
Tolmetin—Visual impairment—Cisplatin—peripheral nervous system neoplasm	0.000836	0.00297	CcSEcCtD
Tolmetin—Dyspepsia—Melphalan—peripheral nervous system neoplasm	0.000829	0.00295	CcSEcCtD
Tolmetin—Agranulocytosis—Etoposide—peripheral nervous system neoplasm	0.000826	0.00294	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000826	0.0103	CbGpPWpGaD
Tolmetin—Constipation—Topotecan—peripheral nervous system neoplasm	0.000822	0.00293	CcSEcCtD
Tolmetin—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000816	0.0029	CcSEcCtD
Tolmetin—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000816	0.0029	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—IFNB1—peripheral nervous system neoplasm	0.000815	0.0102	CbGpPWpGaD
Tolmetin—Tinnitus—Cisplatin—peripheral nervous system neoplasm	0.000809	0.00288	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IFNB1—peripheral nervous system neoplasm	0.000797	0.00998	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—ABCB1—peripheral nervous system neoplasm	0.000796	0.00997	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.000786	0.0028	CcSEcCtD
Tolmetin—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00078	0.00278	CcSEcCtD
Tolmetin—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00078	0.00278	CcSEcCtD
Tolmetin—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.00078	0.00278	CcSEcCtD
Tolmetin—Blood urea increased—Doxorubicin—peripheral nervous system neoplasm	0.000775	0.00276	CcSEcCtD
Tolmetin—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000764	0.00272	CcSEcCtD
Tolmetin—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.000764	0.00272	CcSEcCtD
Tolmetin—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00076	0.00271	CcSEcCtD
Tolmetin—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.00076	0.00271	CcSEcCtD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—CASP3—peripheral nervous system neoplasm	0.000758	0.00949	CbGpPWpGaD
Tolmetin—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000758	0.0027	CcSEcCtD
Tolmetin—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000758	0.0027	CcSEcCtD
Tolmetin—Lymphadenopathy—Epirubicin—peripheral nervous system neoplasm	0.000754	0.00269	CcSEcCtD
Tolmetin—Chest pain—Alitretinoin—peripheral nervous system neoplasm	0.000754	0.00268	CcSEcCtD
Tolmetin—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000754	0.00268	CcSEcCtD
Tolmetin—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000754	0.00268	CcSEcCtD
Tolmetin—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000754	0.00268	CcSEcCtD
Tolmetin—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000754	0.00268	CcSEcCtD
Tolmetin—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.000751	0.00267	CcSEcCtD
Tolmetin—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000748	0.00266	CcSEcCtD
Tolmetin—Flatulence—Cisplatin—peripheral nervous system neoplasm	0.000744	0.00265	CcSEcCtD
Tolmetin—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.000723	0.00257	CcSEcCtD
Tolmetin—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000723	0.00257	CcSEcCtD
Tolmetin—Vascular purpura—Epirubicin—peripheral nervous system neoplasm	0.00072	0.00256	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—GNAS—peripheral nervous system neoplasm	0.000718	0.00899	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Epirubicin—peripheral nervous system neoplasm	0.00071	0.00253	CcSEcCtD
Tolmetin—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000708	0.00252	CcSEcCtD
Tolmetin—Lymphadenopathy—Doxorubicin—peripheral nervous system neoplasm	0.000698	0.00248	CcSEcCtD
Tolmetin—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000697	0.00248	CcSEcCtD
Tolmetin—Oedema—Vincristine—peripheral nervous system neoplasm	0.000697	0.00248	CcSEcCtD
Tolmetin—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00069	0.00246	CcSEcCtD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000686	0.00859	CbGpPWpGaD
Tolmetin—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000685	0.00244	CcSEcCtD
Tolmetin—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000685	0.00244	CcSEcCtD
Tolmetin—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000682	0.00243	CcSEcCtD
Tolmetin—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000676	0.0024	CcSEcCtD
Tolmetin—TDO2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000672	0.00842	CbGpPWpGaD
Tolmetin—Purpura—Epirubicin—peripheral nervous system neoplasm	0.000668	0.00238	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—MYC—peripheral nervous system neoplasm	0.000667	0.00835	CbGpPWpGaD
Tolmetin—Vascular purpura—Doxorubicin—peripheral nervous system neoplasm	0.000666	0.00237	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Epirubicin—peripheral nervous system neoplasm	0.000665	0.00237	CcSEcCtD
Tolmetin—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000658	0.00234	CcSEcCtD
Tolmetin—Cardiac failure congestive—Doxorubicin—peripheral nervous system neoplasm	0.000657	0.00234	CcSEcCtD
Tolmetin—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000653	0.00232	CcSEcCtD
Tolmetin—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000653	0.00232	CcSEcCtD
Tolmetin—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000644	0.00229	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000644	0.00229	CcSEcCtD
Tolmetin—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000643	0.00229	CcSEcCtD
Tolmetin—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000638	0.00227	CcSEcCtD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—IFNB1—peripheral nervous system neoplasm	0.000637	0.00797	CbGpPWpGaD
Tolmetin—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000636	0.00227	CcSEcCtD
Tolmetin—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000636	0.00226	CcSEcCtD
Tolmetin—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000631	0.00225	CcSEcCtD
Tolmetin—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000631	0.00225	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000629	0.00788	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CD34—peripheral nervous system neoplasm	0.000625	0.00783	CbGpPWpGaD
Tolmetin—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000618	0.0022	CcSEcCtD
Tolmetin—Purpura—Doxorubicin—peripheral nervous system neoplasm	0.000618	0.0022	CcSEcCtD
Tolmetin—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000616	0.00219	CcSEcCtD
Tolmetin—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000616	0.00219	CcSEcCtD
Tolmetin—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000616	0.00219	CcSEcCtD
Tolmetin—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000616	0.00219	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Doxorubicin—peripheral nervous system neoplasm	0.000615	0.00219	CcSEcCtD
Tolmetin—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000612	0.00218	CcSEcCtD
Tolmetin—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000607	0.00216	CcSEcCtD
Tolmetin—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000607	0.00216	CcSEcCtD
Tolmetin—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000603	0.00215	CcSEcCtD
Tolmetin—Headache—Topotecan—peripheral nervous system neoplasm	0.000603	0.00214	CcSEcCtD
Tolmetin—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000599	0.00213	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000598	0.00749	CbGpPWpGaD
Tolmetin—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000598	0.00213	CcSEcCtD
Tolmetin—Headache—Tretinoin—peripheral nervous system neoplasm	0.000598	0.00213	CcSEcCtD
Tolmetin—Constipation—Vincristine—peripheral nervous system neoplasm	0.000596	0.00212	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000596	0.00212	CcSEcCtD
Tolmetin—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000591	0.0021	CcSEcCtD
Tolmetin—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000589	0.0021	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	0.000587	0.00735	CbGpPWpGaD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—peripheral nervous system neoplasm	0.000583	0.0073	CbGpPWpGaD
Tolmetin—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.00058	0.00206	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000576	0.00722	CbGpPWpGaD
Tolmetin—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000574	0.00204	CcSEcCtD
Tolmetin—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000572	0.00203	CcSEcCtD
Tolmetin—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000572	0.00203	CcSEcCtD
Tolmetin—Nausea—Topotecan—peripheral nervous system neoplasm	0.000571	0.00203	CcSEcCtD
Tolmetin—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.00057	0.00203	CcSEcCtD
Tolmetin—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.00057	0.00203	CcSEcCtD
Tolmetin—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000567	0.00202	CcSEcCtD
Tolmetin—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000567	0.00202	CcSEcCtD
Tolmetin—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000564	0.00201	CcSEcCtD
Tolmetin—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00056	0.00199	CcSEcCtD
Tolmetin—Nausea—Melphalan—peripheral nervous system neoplasm	0.000559	0.00199	CcSEcCtD
Tolmetin—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000553	0.00197	CcSEcCtD
Tolmetin—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000551	0.00196	CcSEcCtD
Tolmetin—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000551	0.00196	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—TP53—peripheral nervous system neoplasm	0.000548	0.00686	CbGpPWpGaD
Tolmetin—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000536	0.00191	CcSEcCtD
Tolmetin—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000534	0.0019	CcSEcCtD
Tolmetin—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000527	0.00188	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—HRAS—peripheral nervous system neoplasm	0.000524	0.00656	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000522	0.00654	CbGpPWpGaD
Tolmetin—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.00052	0.00185	CcSEcCtD
Tolmetin—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000519	0.00185	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000513	0.00643	CbGpPWpGaD
Tolmetin—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000506	0.0018	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—IFNB1—peripheral nervous system neoplasm	0.000504	0.00632	CbGpPWpGaD
Tolmetin—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000503	0.00179	CcSEcCtD
Tolmetin—CXCL8—IL8- and CXCR1-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.000502	0.00628	CbGpPWpGaD
Tolmetin—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000502	0.00179	CcSEcCtD
Tolmetin—CXCL8—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000501	0.00627	CbGpPWpGaD
Tolmetin—Asthenia—Vincristine—peripheral nervous system neoplasm	0.0005	0.00178	CcSEcCtD
Tolmetin—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000496	0.00177	CcSEcCtD
Tolmetin—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000496	0.00176	CcSEcCtD
Tolmetin—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000495	0.00176	CcSEcCtD
Tolmetin—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000488	0.00174	CcSEcCtD
Tolmetin—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000487	0.00173	CcSEcCtD
Tolmetin—TDO2—Metabolism—GNS—peripheral nervous system neoplasm	0.000486	0.00609	CbGpPWpGaD
Tolmetin—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000484	0.00172	CcSEcCtD
Tolmetin—Constipation—Etoposide—peripheral nervous system neoplasm	0.000483	0.00172	CcSEcCtD
Tolmetin—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000482	0.00172	CcSEcCtD
Tolmetin—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000481	0.00171	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—CASP3—peripheral nervous system neoplasm	0.000478	0.00599	CbGpPWpGaD
Tolmetin—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000478	0.0017	CcSEcCtD
Tolmetin—CXCL8—TSLP Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000478	0.00599	CbGpPWpGaD
Tolmetin—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000477	0.0017	CcSEcCtD
Tolmetin—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000473	0.00168	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000469	0.00588	CbGpPWpGaD
Tolmetin—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000469	0.00167	CcSEcCtD
Tolmetin—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000468	0.00167	CcSEcCtD
Tolmetin—TDO2—Metabolism—NME1—peripheral nervous system neoplasm	0.000466	0.00584	CbGpPWpGaD
Tolmetin—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000466	0.00166	CcSEcCtD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—HRAS—peripheral nervous system neoplasm	0.000465	0.00582	CbGpPWpGaD
Tolmetin—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000463	0.00165	CcSEcCtD
Tolmetin—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000463	0.00165	CcSEcCtD
Tolmetin—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000462	0.00164	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—peripheral nervous system neoplasm	0.000461	0.00577	CbGpPWpGaD
Tolmetin—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000461	0.00164	CcSEcCtD
Tolmetin—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00046	0.00164	CcSEcCtD
Tolmetin—CXCL8—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.00046	0.00576	CbGpPWpGaD
Tolmetin—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000459	0.00163	CcSEcCtD
Tolmetin—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000453	0.00161	CcSEcCtD
Tolmetin—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000451	0.00161	CcSEcCtD
Tolmetin—TDO2—Metabolism—COX2—peripheral nervous system neoplasm	0.000449	0.00562	CbGpPWpGaD
Tolmetin—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000448	0.0016	CcSEcCtD
Tolmetin—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000447	0.00159	CcSEcCtD
Tolmetin—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000446	0.00159	CcSEcCtD
Tolmetin—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000446	0.00159	CcSEcCtD
Tolmetin—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000446	0.00159	CcSEcCtD
Tolmetin—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000445	0.00158	CcSEcCtD
Tolmetin—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000443	0.00158	CcSEcCtD
Tolmetin—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000442	0.00157	CcSEcCtD
Tolmetin—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000438	0.00156	CcSEcCtD
Tolmetin—Headache—Vincristine—peripheral nervous system neoplasm	0.000436	0.00155	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	0.000435	0.00545	CbGpPWpGaD
Tolmetin—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000433	0.00154	CcSEcCtD
Tolmetin—CXCL8—IL8- and CXCR2-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.00043	0.00538	CbGpPWpGaD
Tolmetin—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00043	0.00153	CcSEcCtD
Tolmetin—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000429	0.00153	CcSEcCtD
Tolmetin—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000428	0.00152	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000428	0.00536	CbGpPWpGaD
Tolmetin—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000422	0.0015	CcSEcCtD
Tolmetin—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000421	0.0015	CcSEcCtD
Tolmetin—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000415	0.00148	CcSEcCtD
Tolmetin—Nausea—Vincristine—peripheral nervous system neoplasm	0.000414	0.00147	CcSEcCtD
Tolmetin—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000412	0.00147	CcSEcCtD
Tolmetin—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.000409	0.00512	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	0.000405	0.00507	CbGpPWpGaD
Tolmetin—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000405	0.00144	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—CASP3—peripheral nervous system neoplasm	0.000404	0.00506	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—TP53—peripheral nervous system neoplasm	0.000404	0.00505	CbGpPWpGaD
Tolmetin—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000397	0.00141	CcSEcCtD
Tolmetin—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000392	0.00139	CcSEcCtD
Tolmetin—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.00039	0.00139	CcSEcCtD
Tolmetin—CXCL8—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000388	0.00486	CbGpPWpGaD
Tolmetin—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000386	0.00137	CcSEcCtD
Tolmetin—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000384	0.00137	CcSEcCtD
Tolmetin—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000382	0.00136	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—IFNB1—peripheral nervous system neoplasm	0.000381	0.00477	CbGpPWpGaD
Tolmetin—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000373	0.00133	CcSEcCtD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—peripheral nervous system neoplasm	0.000371	0.00465	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—CDKN2A—peripheral nervous system neoplasm	0.000371	0.00465	CbGpPWpGaD
Tolmetin—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000366	0.0013	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000363	0.00455	CbGpPWpGaD
Tolmetin—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000359	0.00128	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—CASP3—peripheral nervous system neoplasm	0.000358	0.00448	CbGpPWpGaD
Tolmetin—Headache—Etoposide—peripheral nervous system neoplasm	0.000354	0.00126	CcSEcCtD
Tolmetin—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000353	0.00126	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000348	0.00435	CbGpPWpGaD
Tolmetin—CXCL8—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000339	0.00425	CbGpPWpGaD
Tolmetin—Nausea—Etoposide—peripheral nervous system neoplasm	0.000335	0.00119	CcSEcCtD
Tolmetin—CXCL8—TSLP Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000332	0.00415	CbGpPWpGaD
Tolmetin—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.00033	0.00117	CcSEcCtD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000325	0.00407	CbGpPWpGaD
Tolmetin—CXCL8—IL-3 Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000321	0.00402	CbGpPWpGaD
Tolmetin—MPO—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	0.000318	0.00399	CbGpPWpGaD
Tolmetin—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000316	0.00113	CcSEcCtD
Tolmetin—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000316	0.00113	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—peripheral nervous system neoplasm	0.000312	0.00391	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.00031	0.0011	CcSEcCtD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000308	0.00386	CbGpPWpGaD
Tolmetin—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.00109	CcSEcCtD
Tolmetin—CXCL8—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000295	0.0037	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—ENO2—peripheral nervous system neoplasm	0.000295	0.00369	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—HRAS—peripheral nervous system neoplasm	0.000293	0.00367	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	0.000293	0.00367	CbGpPWpGaD
Tolmetin—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.00104	CcSEcCtD
Tolmetin—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.00104	CcSEcCtD
Tolmetin—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.00102	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—TP53—peripheral nervous system neoplasm	0.000286	0.00358	CbGpPWpGaD
Tolmetin—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000281	0.001	CcSEcCtD
Tolmetin—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000279	0.000991	CcSEcCtD
Tolmetin—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000963	CcSEcCtD
Tolmetin—CXCL8—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000268	0.00336	CbGpPWpGaD
Tolmetin—SLC22A6—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000265	0.00332	CbGpPWpGaD
Tolmetin—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000926	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—AKT1—peripheral nervous system neoplasm	0.000259	0.00324	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000921	CcSEcCtD
Tolmetin—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000258	0.000917	CcSEcCtD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000258	0.00323	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—BDNF—peripheral nervous system neoplasm	0.000257	0.00322	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000257	0.00322	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—peripheral nervous system neoplasm	0.000255	0.0032	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000254	0.00319	CbGpPWpGaD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—TP53—peripheral nervous system neoplasm	0.000252	0.00315	CbGpPWpGaD
Tolmetin—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000251	0.000895	CcSEcCtD
Tolmetin—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000891	CcSEcCtD
Tolmetin—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.00025	0.00089	CcSEcCtD
Tolmetin—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.00025	0.00089	CcSEcCtD
Tolmetin—TDO2—Metabolism—BCHE—peripheral nervous system neoplasm	0.000249	0.00312	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000239	0.000852	CcSEcCtD
Tolmetin—TDO2—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000237	0.00297	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—CDKN2A—peripheral nervous system neoplasm	0.000235	0.00294	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000235	0.00294	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000235	0.00294	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—TH—peripheral nervous system neoplasm	0.000234	0.00293	CbGpPWpGaD
Tolmetin—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000828	CcSEcCtD
Tolmetin—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000824	CcSEcCtD
Tolmetin—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.000824	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	0.000229	0.00287	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000229	0.00287	CbGpPWpGaD
Tolmetin—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000808	CcSEcCtD
Tolmetin—CXCL8—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000224	0.0028	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	0.000218	0.00273	CbGpPWpGaD
Tolmetin—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000216	0.00077	CcSEcCtD
Tolmetin—PTGS1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000214	0.00268	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000213	0.00267	CbGpPWpGaD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—AKT1—peripheral nervous system neoplasm	0.000212	0.00266	CbGpPWpGaD
Tolmetin—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000748	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.00021	0.00262	CbGpPWpGaD
Tolmetin—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000209	0.000745	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—TP53—peripheral nervous system neoplasm	0.000206	0.00259	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000205	0.00257	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000203	0.00254	CbGpPWpGaD
Tolmetin—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000716	CcSEcCtD
Tolmetin—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.000713	CcSEcCtD
Tolmetin—Headache—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000705	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—HRAS—peripheral nervous system neoplasm	0.000197	0.00247	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000194	0.00243	CbGpPWpGaD
Tolmetin—CXCL8—Corticotropin-releasing hormone—AKT1—peripheral nervous system neoplasm	0.000194	0.00243	CbGpPWpGaD
Tolmetin—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.000689	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000191	0.00239	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—GNAS—peripheral nervous system neoplasm	0.000191	0.00239	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—BCHE—peripheral nervous system neoplasm	0.000188	0.00236	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	0.000188	0.00235	CbGpPWpGaD
Tolmetin—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000188	0.000669	CcSEcCtD
Tolmetin—CXCL8—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000187	0.00235	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000187	0.00235	CbGpPWpGaD
Tolmetin—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000662	CcSEcCtD
Tolmetin—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000653	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000178	0.00223	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	0.000177	0.00222	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000175	0.00219	CbGpPWpGaD
Tolmetin—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000174	0.000619	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000172	0.00215	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00017	0.00213	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	0.000167	0.0021	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000158	0.00198	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000152	0.0019	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000145	0.00181	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	0.000141	0.00177	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	0.000139	0.00174	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000135	0.00169	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000133	0.00166	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	0.000132	0.00165	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—TP53—peripheral nervous system neoplasm	0.000131	0.00164	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—CASP3—peripheral nervous system neoplasm	0.000128	0.00161	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.00012	0.00151	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.00012	0.0015	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00012	0.0015	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000116	0.00145	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000115	0.00144	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000111	0.00139	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000108	0.00136	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000106	0.00133	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000105	0.00132	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GNS—peripheral nervous system neoplasm	0.000105	0.00131	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	0.000103	0.00129	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—MYC—peripheral nervous system neoplasm	0.0001	0.00126	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NME1—peripheral nervous system neoplasm	0.0001	0.00125	CbGpPWpGaD
Tolmetin—PTGS2—Disease—GNS—peripheral nervous system neoplasm	9.91e-05	0.00124	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—TP53—peripheral nervous system neoplasm	9.87e-05	0.00124	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—COX2—peripheral nervous system neoplasm	9.64e-05	0.00121	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	9.63e-05	0.00121	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	9.54e-05	0.00119	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	8.74e-05	0.00109	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.32e-05	0.00104	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GNS—peripheral nervous system neoplasm	8.3e-05	0.00104	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TP53—peripheral nervous system neoplasm	8.24e-05	0.00103	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NME1—peripheral nervous system neoplasm	7.95e-05	0.000996	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—COX2—peripheral nervous system neoplasm	7.66e-05	0.000959	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.32e-05	0.000917	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.12e-05	0.000891	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PPP3R1—peripheral nervous system neoplasm	6.93e-05	0.000868	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	6.82e-05	0.000854	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.78e-05	0.000849	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ENO2—peripheral nervous system neoplasm	6.33e-05	0.000793	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.22e-05	0.000779	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ENO2—peripheral nervous system neoplasm	6e-05	0.000752	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	5.6e-05	0.000702	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—BCHE—peripheral nervous system neoplasm	5.35e-05	0.00067	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—AKT1—peripheral nervous system neoplasm	5.16e-05	0.000646	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.1e-05	0.000639	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—TH—peripheral nervous system neoplasm	5.03e-05	0.00063	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ENO2—peripheral nervous system neoplasm	5.03e-05	0.00063	CbGpPWpGaD
Tolmetin—PTGS2—Disease—SLC2A1—peripheral nervous system neoplasm	4.84e-05	0.000606	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.73e-05	0.000593	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.4e-05	0.000551	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.32e-05	0.000542	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—BCHE—peripheral nervous system neoplasm	4.25e-05	0.000532	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GNAS—peripheral nervous system neoplasm	4.11e-05	0.000514	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.05e-05	0.000507	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ABCB1—peripheral nervous system neoplasm	4.03e-05	0.000505	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—TH—peripheral nervous system neoplasm	3.99e-05	0.0005	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.42e-05	0.000428	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GNAS—peripheral nervous system neoplasm	3.26e-05	0.000408	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.22e-05	0.000403	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ABCB1—peripheral nervous system neoplasm	3.2e-05	0.000401	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.13e-05	0.000392	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.1e-05	0.000388	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.84e-05	0.000356	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PTPN11—peripheral nervous system neoplasm	2.7e-05	0.000339	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.6e-05	0.000326	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.42e-05	0.000303	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ERBB2—peripheral nervous system neoplasm	2.14e-05	0.000268	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.99e-05	0.000249	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.9e-05	0.000238	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.68e-05	0.00021	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NRAS—peripheral nervous system neoplasm	1.63e-05	0.000204	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MYC—peripheral nervous system neoplasm	1.51e-05	0.00019	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HRAS—peripheral nervous system neoplasm	1.19e-05	0.000149	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—AKT1—peripheral nervous system neoplasm	1.11e-05	0.000139	CbGpPWpGaD
Tolmetin—PTGS2—Disease—AKT1—peripheral nervous system neoplasm	1.05e-05	0.000132	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—AKT1—peripheral nervous system neoplasm	8.8e-06	0.00011	CbGpPWpGaD
